Introduction to Section 3
Section 3 of the Patents Act, 1970 lists what are NOT considered inventions within the meaning of the Act. These exclusions represent policy choices by the legislature to deny patent protection for certain subject matter, even if technically novel and inventive.
Understanding Section 3 is critical for patent practitioners because:
- These exclusions cannot be overcome by clever claim drafting
- Many patent applications are rejected or opposed based on Section 3
- India's Section 3 is more restrictive than many other jurisdictions
- Section 3(d) in particular has global significance for pharmaceutical patents
Section 3(a) - Contrary to Law, Morality, Public Order
This provision excludes:
- Frivolous inventions: Those with no utility or practical application
- Violations of natural laws: Such as perpetual motion machines or devices claiming to violate thermodynamics
The Controller may reject applications for devices claiming unlimited energy output, anti-gravity machines, or other inventions that violate fundamental scientific principles without requiring detailed examination.
Section 3(b) - Public Order and Morality
Examples of inventions excluded under Section 3(b):
- Weapons designed primarily for torture
- Processes for human cloning
- Genetic modification creating environmental hazards
- Letter bombs or anti-personnel mines
This provision aligns with Article 27.2 of TRIPS which allows members to exclude inventions necessary to protect ordre public, morality, human/animal/plant life, health, or the environment.
Section 3(c) - Discovery vs Invention
This provision distinguishes between:
Discovery (Not Patentable)
- Finding something already existing in nature
- Scientific principles (e.g., laws of thermodynamics)
- Mathematical theories or formulas
- Natural phenomena
Invention (Patentable)
- Practical application of a discovery
- Process for isolating natural substances
- Modified forms of natural substances with improved properties
Finding a new microorganism is a discovery. Developing a process to use that microorganism to produce an antibiotic may be an invention. The key is whether human intervention has created something that did not exist in nature in that form.
Section 3(d) - The Anti-Evergreening Provision
Explanation: For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy.
Section 3(d) is India's most significant and controversial patent provision. It was introduced in the 2005 Amendment specifically to prevent "evergreening" - the practice of obtaining successive patents on minor modifications to extend monopoly protection.
Key Requirements Under Section 3(d)
- Known Substance: The provision applies only when a patent is sought for a new form of a known substance
- Enhanced Efficacy: The new form must show enhanced efficacy compared to the known substance
- Significant Difference: Derivatives must differ significantly in properties with regard to efficacy
The "Efficacy" Question
Section 3(d) does not define "efficacy." The interpretation of this term was central to the Novartis case:
- For pharmaceuticals: Does efficacy mean therapeutic efficacy only?
- Can improved bioavailability, stability, or reduced toxicity constitute enhanced efficacy?
- What evidence is required to demonstrate enhanced efficacy?
Landmark Case: Novartis AG v. Union of India
Background
Novartis sought a patent for the beta-crystalline form of imatinib mesylate (sold as Glivec/Gleevec), an anti-cancer drug. The original compound imatinib was developed in the 1990s but was not patented in India as product patents for pharmaceuticals were not available then.
The Application
In 1998, Novartis filed a patent application for the beta-crystalline form claiming it had superior properties over the free base form - better flow, thermodynamic stability, and lower hygroscopicity.
The Opposition
Multiple pre-grant oppositions were filed by generic manufacturers and patient groups arguing the application violated Section 3(d) as it was merely a new form of a known substance without enhanced efficacy.
Key Issues Before the Supreme Court
- What is the meaning of "efficacy" in Section 3(d)?
- Does imatinib mesylate beta-crystalline form show enhanced efficacy over imatinib?
- Is Section 3(d) TRIPS compliant?
Supreme Court Judgment
On Efficacy: The Court held that for pharmaceutical substances, "efficacy" means "therapeutic efficacy" - the ability to produce a desired therapeutic effect. Physical properties like better flow or stability do not constitute enhanced efficacy unless they translate to improved therapeutic effect.
On the Patent: The Court rejected Novartis's patent application holding that mere 30% improvement in bioavailability did not demonstrate enhanced therapeutic efficacy. The beta-crystalline form was the same substance as imatinib freebase for purposes of Section 3(d).
On TRIPS: The Court upheld Section 3(d) as TRIPS compliant, noting that TRIPS allows flexibility in defining patentability standards.
For India: Established high threshold for pharmaceutical patents on new forms. Generic industry protected. Access to medicines prioritized.
Globally: Influenced other developing countries. Some have adopted similar provisions. Remains controversial with innovator pharmaceutical industry.
Sections 3(e) to 3(p) - Complete Analysis
A substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof or a process for producing such substance.
Rationale: Simply mixing known components without synergy is not inventive.
Exception: If the mixture shows unexpected synergistic effect beyond mere aggregation, it may be patentable.
The mere arrangement or re-arrangement or duplication of known devices each functioning independently of one another in a known way.
Example Excluded: Placing two fans side by side to increase airflow.
Example Patentable: Arrangement where devices interact to produce unexpected technical effect.
A method of agriculture or horticulture.
Rationale: Ensures farmers can use traditional and new farming methods freely.
Note: Agricultural implements and agrochemicals can still be patented.
Any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products.
Rationale: Doctors should not be constrained in treating patients. Medical ethics concerns.
Note: Devices used in treatment and pharmaceutical compositions remain patentable.
Plants and animals in whole or any part thereof other than microorganisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals.
Patentable: Microorganisms, non-biological processes, microbiological processes.
Not Patentable: Plant varieties (protected under PPV&FR Act), animal breeds, seeds.
A mathematical or business method or a computer programme per se or algorithms.
Key Term: "Per se" - programs in isolation are excluded, but technical applications may be patentable.
Indian Patent Office Guidance: Software with technical effect beyond ordinary computer operation may qualify for patent protection.
A literary, dramatic, musical or artistic work or any other aesthetic creation whatsoever including cinematographic works and television productions.
Rationale: These are protected under Copyright Law, not patent law.
A mere scheme or rule or method of performing mental act or method of playing game.
Examples Excluded: Rules of chess, teaching methods, mnemonic techniques.
A presentation of information.
Rationale: How information is displayed or organized is not a technical invention.
Topography of integrated circuits.
Note: Protected under the Semiconductor Integrated Circuits Layout-Design Act, 2000.
An invention which in effect, is traditional knowledge or which is an aggregation or duplication of known properties of traditionally known component or components.
Rationale: Protects against biopiracy and misappropriation of traditional knowledge.
Example: Turmeric wound healing patent revoked based on traditional knowledge.